WEDNESDAY, SEPTEMBER 28, 2016

Nuron Biotech announces new president/CEO, senior VP and CBO

Nuron Biotech, Inc., a vaccine and specialty biologics company, announced on Thursday the appointment of Dr. Warren D. Cooper, Dr. Daniel Cushing and Kevin Taylor to its executive team.

Nuron announced Cooper as the new interim president and CEO of the company; Cooper will also serve on Nuron's board of directors. Cooper was recently the CEO of Prism Pharmaceuticals and has more than 30 years of experience in the global pharmaceutical industry.

Nuron announced Cushing as the company's new senior vice president of research and development. Cushing will be responsible for organizing clinical and nonclinical developments, including quality assurance, quality control and program management.

"Dan has over 20 years of pharmaceutical industry experience with demonstrated commitment to scientific and regulatory excellence" Cooper said. "Over his career Dan has led the successful development registration and launch of multiple products that still enjoy success in the market. Dan and I have worked closely together in several successful ventures including AstraMerck and Prism Pharmaceuticals and I am confident in his ability to drive prudent decisions that will shape support and advance Nuron's pipeline and commercial business."

Nuron also announced Taylor will join the company as its chief business officer.

"Kevin brings over 20 years of experience in corporate and business development in the global pharmaceutical industry supporting both R&D and commercial operations" Cooper said. "Kevin will continue to strengthen the critical business relationships currently in place at Nuron and is focused on finding and fostering new partnering relationships that are strategically aligned to Nuron's business."